Navigation Links
Study shows surgery provides good long-term outcomes for patients with gastrointestinal cancers
Date:1/14/2009

CHICAGO (January 14, 2009) New research published in the January issue of the Journal of the American College of Surgeons shows that laparoscopic removal of gastrointestinal stromal tumors (GISTs) is safe and effective, with a disease-free survival rate of nearly 80 percent after an average follow-up time of three and a-half years.

GIST is a type of cancer arising from special cells in the wall of the gastrointestinal tract that help coordinate the muscular movement of digestive organs. Each year, between 4,500 and 6,000 cases of GIST are diagnosed in the United States. Laparoscopic surgery is an attractive alternative to traditional "open" surgery the treatment of choice for GISTs that have not spread to nearby organs since it is requires smaller abdominal incisions and therefore may be safer and result in a quicker recovery.

"Based on our data, which represents the largest retrospective series of GIST patients reported to date, we believe that laparoscopic resection is feasible in the management of these tumors, carries no additional risks and has comparable results to the open approach," said Celia Divino, MD, FACS, Chief, Division of General Surgery at The Mount Sinai Medical Center, New York, N.Y.

Parissa Tabrizian, MD, further noted that, "The biologic behavior of GISTs makes them amenable to laparoscopic resection because they do not require removal of large amounts of tissue or lymph nodes."

Researchers conducted a retrospective study to evaluate long-term outcomes and survival in 76 patients who underwent laparoscopic treatment of GIST. Tumors were located in the stomach (72 percent) and the small bowel (28 percent).

At a mean follow-up of 41 months (range, 3 to 102 months), the overall disease-free survival rate was 78 percent (77 percent for gastric tumors and 82 percent for small bowel tumors). Three percent of patients died of metastatic disease, and nine percent of patients died from other unre
'/>"/>

Contact: Sally Garneski, ACS
pressinquiry@facs.org
312-202-5409
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1 2

Related medicine news :

1. TPHAC Reaction to Economic Impact Study
2. First-of-Its Kind Study: Medicare for All (Single-Payer) Reform Would Be Major Stimulus for Economy With 2.6 Million New Jobs, $317 Billion in Business Revenue, $100 Billion in Wages
3. National Children's Study Begins Recruiting Volunteers
4. Study shows workplace benefits of influenza vaccination in 50-64 year olds
5. Study: Most young violent offenders in two NYC neighborhoods have seen someone killed
6. National Childrens Study Begins Recruiting Volunteers
7. InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA
8. UNC study supports role of circadian clock in response to chemotherapy
9. Medical study shows epidurals and spinal anesthetics are safer than previously reported
10. InterMune Reports Results from Triple Combination Study of ITMN-191
11. LegalView Reports Traumatic Brain Injury Study Concluding Spirituality Increases Following Brain Damage
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 2Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 3Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 4Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 5Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 2Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 3Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 4Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 5Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 7Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 8Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 10Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 11Octapharma Aims to Expand U S Immune Globulin Therapy Portfolio 14224 1Octapharma Aims to Expand U S Immune Globulin Therapy Portfolio 14224 2Octapharma Aims to Expand U S Immune Globulin Therapy Portfolio 14224 3Oxygen Biotherapeutics Inc Receives Phase II Trial Approval in Israel 5033 1Oxygen Biotherapeutics Inc Receives Phase II Trial Approval in Israel 5033 2Discovery could improve hepatitis C treatment 58129 1Discovery could improve hepatitis C treatment 58129 2